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ABSTRACT  
BACKGROUND AND AIM A potential increased risk of cardiovascular events has been suggested for 
proton pump inhibitors (PPIs), the most commonly prescribed drugs for the management of upper 
gastrointestinal disorders. We aimed to estimate the risk of hospitalization for 
cardio/cerebrovascular (CV) events in a cohort of incident PPI users. 
METHODS A nested case-control study was carried out using regional healthcare utilization 
databases. For each case (hospitalization for non-haemorrhagic CV event), up-to-five controls 
randomly selected from the cohort were matched by gender, age at cohort entry, and index date. 
Exposure was estimated as recency of therapy (current, recent and past users) and number of days 
covered. Adjusted conditional logistic regression was used to estimate the association between 
exposure and outcome.  
RESULTS Among new PPI users, we identified 17,832 cases and 89,160 controls (males 64.9%; mean 
age 58.9 years). Cases showed a significantly higher prevalence of use of drugs for diabetes, 
hypertension and hypercholesterolemia than controls. Risk of CV events was significantly higher for 
current (OR 1.61; 95%CI 1.55-1.68) and recent users (OR 1.15; 95%CI 1.06-1.26) compared to past 
users. Analogous results were found stratifying for cardiovascular (ORcurrent 1.71; 95%CI 1.63-1.81) 
and cerebrovascular events (ORcurrent 1.43; 95%CI 1.34-1.54). The increased risk was confirmed in 
subgroups by antithrombotic, statin use, or exposure duration. The same analysis for H2-antagonists 
use showed no significant results. 
CONCLUSIONS In primary care setting, PPI use was independently associated with increased risk of 
first-time cardiovascular event, consistent with the evidence that PPIs adversely impact vascular 
function, underlying the need to promote appropriate prescribing of these drugs. 
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INTRODUCTION 
Proton pump inhibitors (PPIs) are among the most commonly prescribed drugs for the management 
of upper gastrointestinal disorders, such as gastroesophageal reflux disease (GERD), peptic or 
duodenal ulcer disease and dyspepsia (1, 2). Increasing of GERD prevalence in Western countries 
and Asia during the last 20 years as well as the undoubted effectiveness of these drugs are 
extensively demonstrated by previous studies (3, 4). Furthermore, the beneficial effects even after 
short-term therapy with an improvement of patient’s quality of life, together with the belief that 
PPIs are essentially safe, lead to a widespread prescription of these drugs (5). Indeed, several 
publications have shown the inappropriate use of these drugs during hospitalization as well as in 
primary care (6, 7). Within this scenario, a potential increased risk of serious adverse drug reactions 
as cardiovascular and cerebrovascular events has been reported and is a matter of concern (8-10).  
The increased cardiovascular morbidity in patients exposed to PPIs was firstly related to a potential 
interaction with clopidogrel (11, 12). As a consequence, based on the results of two long-term 
randomized controlled trials (RCTs) showing that severe cardiovascular events were more common 
in patients with GERD being treated with omeprazole or esomeprazole compared to subjects 
undergoing to surgery (13, 14), in 2009 the Food and Drug Administration (FDA) issued a safety 
warning recommending to avoid the co-administration because it could result in significant 
reductions in clopidogrel's active metabolite levels and antiplatelet activity. Even if concerns remain 
on the epidemiology of this interaction and the intensity of the clinical effect, several more recent 
studies have found that PPIs may independently affect vascular function (15-18) and a recent meta-
analysis of 16 RCTs showed a significant 70% increased risk of cardiovascular events among patients 
treated with PPIs as monotherapy (17).  
The correct evaluation and quantification of an increase in cardiovascular risk associated with the 
use of PPIs is essential in the context of widespread and sometimes unnecessary use of these drugs. 
Therefore, we conducted a nested case-control study aimed to estimate the risk of hospitalization 
for cardiovascular and cerebrovascular events associated with PPI exposure. 
 
 
 
METHODS 
 
Data source  
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In Italy, the National Health Service (NHS) provides universal, free-of-charge coverage to all 
inhabitants for many healthcare services. For the present study, data were retrieved from the 
healthcare utilization databases of the Italian Lombardy region. The regional automated system of 
databases collects a variety of information (19), including: 
(1) an archive of residents who receive NHS assistance, reporting demographic and administrative 
data; 
(2) a database of the outpatient drug prescriptions reimbursable by the NHS; 
(3) a database on diagnosis at discharge from public or private hospitals of the region. 
For each patient, we linked the aforementioned databases via a single identification code. In order 
to preserve privacy, each identification code was automatically converted into an anonymous code; 
the inverse process was prevented by deletion of the conversion table.  
 
Cohort selection and follow-up 
The target population consists of all beneficiaries of the NHS, resident in Lombardy with age >=18 
and <=70 years. A cohort of incident PPI users was identified. Exposure to PPI was inferred from the 
presence of prescriptions for any drug belonging to the class in the prescription database. Since in 
Italy the availability of these drugs as OTC started at the end of 2010, this approach guarantees the 
correct identification of exposed patients during the study period. Subjects with at least one 
prescription of PPIs (ATC A02BC) from January 1, 2003 until December 31, 2007 were identified, and 
the date of first prescription was defined as the index date.  
Patients were excluded from data analysis if: i) they had received any PPIs within the 3 years before 
the index date to ensure the selection of only incident users of PPIs; ii) they had received any 
histamine-2 receptor (H2) antagonists drugs within the 3 years before the index date and/or during 
follow-up to explore the effect of PPIs excluding the potential effect of other drugs with similar 
indication; iii) they were hospitalized for any cardiovascular or cerebrovascular events or they were 
treated with any anticoagulant or antiplatelet therapy (regardless if primary or secondary 
prevention) in the 3 years before the index date to avoid the inclusion of patients with previous 
cardiovascular problems; iv) they were hospitalized for tumours or cancer treatments in the 3 years 
before the index date; v) they had less than 57 days of follow-up from index date to ensure that all 
subjects have the same probability of falling in any of the exposure category. Each member of the 
cohort accumulated person-years of follow-up from the index date until the earliest event among: 
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hospitalization for any cardiovascular or cerebrovascular events (see below), death, emigration, or 
end of follow-up (December 31, 2010). 
 
 
Selection of cases and controls 
A nested case-control study was performed into the cohort of incident PPIs users. Cases were 
members of the cohort who during follow-up were hospitalized for ischemic heart disease (ICD-9 
code 410-414, 425, 427, 428) and/or cerebrovascular disease excluding haemorrhagic events (ICD-
9 code 433-435). The earliest date of hospital admission was considered as the event date. 
For each case patient, up to five controls randomly selected from the cohort were matched by 
gender, age at cohort entry, and index date. In this way, every set constituted by the index case and 
the corresponding controls had the same period of observation. 
 
Assessing exposure to PPIs 
Exposure was evaluated as: 
- recency, which quantifies the time from the last day of prescription during follow-up and the 
event date. Specifically, we defined: 
 current users, having the last day covered by PPI therapy within 28 days before event 
date; 
 recent users, having the last day covered by PPI therapy between 29 and 56 days 
before event date; 
 past users, having the last day covered by PPI therapy more than 56 days before event 
date; 
- days covered by therapy, calculated as the cumulative number of days of therapy, based on the 
defined daily dose (DDD), estimated in the last continuous coverage period (cut-off at 28 daily 
doses of exposure to PPIs). 
 
Covariates 
The information on several confounding variables were also retrieved. As data on diagnosis are not 
included in the administrative databases, we considered the use of antidiabetic (ATC A10B), 
antihypertensive (C02, C03, C07, C08, C09) and lipid-lowering drugs (C10A) as a proxy for the 
presence of diabetes, hypertension and hypercholesterolemia, respectively. The use of these drugs, 
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NSAID (Non-Steroidal Anti-Inflammatory Drug) use except coxibs (M01AA, M01AB, M01AC, M01AE, 
M01AG, M01AX), coxib use (M01AH), corticosteroid use (H02AB, H02BX01) and the Charlson 
comorbidity index (20) were evaluated both in the 3 years before index date and during follow-up, 
while the antithrombotic use (ATC B01A) was assessed only during follow-up. 
 
Data analysis  
Chi-square and t tests were used to evaluate the differences between cases and controls of 
categorical and continuous variables respectively. Conditional logistic regression models were fitted 
to estimate the adjusted odds ratio (aOR) and the corresponding 95% confidence interval (CI), of 
cardiovascular (CV) events in relation to exposure to PPIs. Adjustments were made for type of PPI 
and the above reported covariates. The analyses were performed considering as outcome the 
hospitalization for any cardiovascular disease and separately cardiovascular and cerebrovascular 
events. Trends in aORs were tested, when feasible, according to the statistical significance of the 
regression coefficient of the recorded variables obtained by scoring the corresponding categories. 
Moreover, a stratified analysis was performed considering the following variables: use of 
antithrombotics, statins, antidiabetic and antihypertensive drugs used during follow-up, age (≤60 vs 
>60 years) and gender to assess if the effect of the current use of PPIs on the onset of CV disease 
varied among strata. The differences between strata were tested including in the model an 
interaction term between exposure and stratification variables. 
All analyses were performed using the Statistical Analysis System Software (version 9.4; SAS 
Institute, Cary, NC, USA). Statistical significance was set at the 0.05 level. All p-values were two-
sided. 
 
Sensitivity analyses 
To verify the robustness of our findings, we performed the following sensitivity analyses.  
The same analysis described above was repeated modifying the definition of recency: first, with 
different windows of exposure (current users ≤14 days, recent users 15-28 days; past users >28 
days); second, considering the prescription date instead of the last day covered (current users as 
having last prescription of PPIs within 28 days before event date; recent users as having the last 
prescription of PPIs between 29 and 56 days before event date; past users as having the last 
prescription of PPIs over than 56 days before event date). 
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Furthermore, to test a possible indication bias, we conducted a parallel case-control study nested 
in a cohort of incident users of H2 antagonists, a different class of drugs with the same therapeutic 
indications as PPIs, excluding patients who had received any PPIs within the 3 years before the index 
date and/or during follow-up. The definitions for exposure and events were the same used in the 
main PPI analysis. 
 
 
 
RESULTS 
 
According to our inclusion and exclusion criteria (Supplemental Figure 1), we enrolled 737,369 
subjects aged 18-70, free from cardiovascular disease at cohort entry, non-users of antithrombotic 
drugs or H2 antagonists, and with at least 57 days of follow-up, who were incident users of PPIs in 
the period 2003-2007. Within this cohort, we identified 17,832 case patients with a hospitalization 
for ischemic heart disease (N 11,616) and/or non-hemorrhagic cerebrovascular disease (N 6467) 
and matched them with 89,160 controls. 
As shown in Table 1, mean age (SD) of cases and controls was 58.89 years (9.05 years) and 64.9% of 
them were men (matching variables). Esomeprazole, omeprazole, and lansoprazole were the PPI 
agents more commonly prescribed. As compared to controls, use of drugs for diabetes, 
hypertension, or hypercholesterolemia was more common among cases, as well as the comorbidity 
(by Charlson score) was higher, while use of non-selective NSAIDs or coxibs was not different 
between cases and controls. Distribution by recency classes was quite different: current users 
represented 24.6% of cases and 14.4% of controls. 
 
Table 1. Characteristics of the case patients and of the corresponding controls included into the study  
 
 
In the multivariable-adjusted regression analysis, risk of CV events was significantly higher for 
current (aOR 1.61, 95%CI 1.55-1.68) and recent users (aOR 1.15, 95%CI 1.06-1.26) compared to past 
users (Table 2). There was no statistical evidence that the effect of PPIs on cardiovascular risk 
differed according to type of PPI, as prescribed at starting therapy. 
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Table 2. Association between PPI use and risk of hospitalization for cardiovascular or non-haemorrhagic 
cerebrovascular events 
 
 
Results were confirmed by the stratified analysis for cardiovascular (current: aOR 1.71, 95%CI 1.63-
1.81) and cerebrovascular events (current: aOR 1.43, 95%CI 1.34-1.54) (Table 3).  
 
Table 3. Association between PPI use and risk of hospitalization for cardiovascular and non-haemorrhagic 
cerebrovascular events  
 
 
The increased risk was not influenced by exposure duration: compared to past users, the aOR for 
current users with ≤28 daily doses (67.2% of current cases and 69.2% of current controls) was 1.61 
(95%CI 1.53-1.69) and for current users with >28 daily doses was 1.62 (95%CI 1.51-1.73). In the 
comparison between current users ≤28 daily doses vs current users >28 daily doses, OR was 0.99 
(95%CI 0.92-1.07).  
 
The stratified analysis (Figure 1) showed a significant difference among strata of antithrombotic use 
during follow-up (p-value 0.002) and age (p-value <0.0001). In particular, antithrombotic users had 
an higher risk of CV events compared to non-users (aOR 1.74 vs 1.52) as well as younger subjects 
compared to older ones (aOR 1.78 vs 1.50). 
 
Figure 1. Association between current use of PPIs (vs past use) and risk of hospitalization for cardiovascular 
or non-haemorrhagic cerebrovascular events by age, gender, or concomitant use of drugs 
 
 
The results were also confirmed by the sensitivity analysis, which tested different definitions of PPI 
use recency (Supplemental Table 1). 
 
Finally, we evaluated whether the increased risk of cardiovascular and cerebrovascular events 
observed with current vs past PPI use was also present among current users vs past users of H2 
antagonists. In this nested case-control study, we identified 427 case patients, matched with 2,133 
controls; mean age (SD) of cases and controls was 58 years (9.7 years) and 68.6% of them were men. 
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Distribution by recency classes was similar (p-value 0.8179) between cases and controls (current 
users represented 4.5% of cases and 3.5% of controls). The multivariable-adjusted regression 
analysis on the effect of H2 antagonists use showed no significant results (Table 4). 
 
Table 4. Risk of hospitalization for cardiovascular or non-haemorrhagic cerebrovascular events by recency of 
H2 antagonist use 
 
 
 
DISCUSSION 
 
Proton pump inhibitors are the most effective gastric acid-suppressing agents and have 
revolutionized the treatment of upper gastrointestinal tract disorders and the prevention of gastric 
complications associated with the use of non-steroidal anti-inflammatory drugs (21). Their 
effectiveness and their favourable tolerance profile have made them one of the most used drug 
classes. However, PPIs are used too often or too long in patients with insufficient indications (8, 9). 
Concern about their over-utilization has led to investigate potential adverse effects, and recent 
literature has suggested a number of safety issues associated with the use of PPIs (10, 22, 23), 
including increase of cardiovascular risk. 
 
Early evidence of increased cardiovascular risk associated with pump-inhibitor therapy dates back a 
decade ago (24, 25), when it was suggested that omeprazole administration in clopidogrel-treated 
patients could inhibit CYP2C19, responsible for the activation of the prodrug clopidogrel, with 
consequent reduction in antiplatelet activity and increased CV risk. Along with these data, evidence 
has been collected over time in favor of possible PPI effects on cardiovascular outcome regardless 
of antiplatelet therapy. To evaluate whether PPI use associates with first-time myocardial infarction 
in the general population, Shih et al. (16) designed a propensity score-matched study and a case-
crossover study. They found a hazard ratio of 1.58 (95%CI 1.11–2.25) in the analysis of PPI use 
periods matched to PPI non-use periods, and an aOR of 4.61 (95%CI 1.76–12.07) in the case-
crossover analysis (1–7 days before the index date vs 8–14 days before the index date). The same 
analysis was conducted using H2 antagonists as negative control and NSAIDs as positive controls, 
yielding in a non-significant result and in an aOR of 1.55 (95%CI 1.27-1.89), respectively. Similarly, 
Wang et al. (18) studied the association with first-time ischemic stroke using a propensity score-
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matched study and a nested case-control study. They found a hazard ratio of 1.36 (95%CI 1.14–1.62) 
in the analysis of PPI use periods matched to PPI non-use periods, which remained significant 
comparing to H2 antagonist use (HR 1.49; 95%CI 1.10-2.02). In the nested case-control analysis on 
more than 30.000 subjects, they found aORs of 1.77 (95%CI 1.45–2.17) within 30 days before the 
hospitalization of first-time ischemic stroke, 1.65 (95%CI 1.31–2.08) between 31 and 90 days, and 
1.28 (95%CI 1.03–1.59) between 91 and 180 days before the event, as compared with those without 
stroke, while the proportions of H2 antagonist users and non-users were comparable. Of note, these 
studies were conducted using data from the National Health Insurance Research Database of Taiwan 
and, according to the Taiwan Bureau of NHI, reimbursement guidance on PPI prescriptions is limited 
to patients with peptic ulcer disease with or without complications or gastroesophageal reflux 
disease, with a treatment duration mostly limited to 4 months. Shah et al. (26) investigated the 
association between PPIs and MI using an innovative data mining approach and showing that PPIs 
as a class were associated with MI with an aOR of 1.16 (95%CI 1.09–1.24); the associations persist 
after excluding patients on clopidogrel (aOR 1.14; 95%CI 1.06–1.24), while no association was 
showed for H2 antagonists (aOR 0.93; 95%CI 0.86–1.02). Moreover, in a prospective cohort of 
patients undergoing elective coronary angiography, survival analysis revealed an increased 
cardiovascular mortality among PPI users during about 5 years of follow-up (HR 2.00, 95%CI 1.07–
3.78). Recently, in a study of Danish individuals without prior atherosclerotic disease, PPI use was 
associated with a significantly increased risk of ischemic stroke (HR 1.13; 95%CI 1.08-1.19) and MI 
(HR 1.31; 95%CI 1.23-1.39), with a dose–response relationship, and no significant association 
between use of H2 antagonists (27). In our study, a nested case-control study in a cohort of incident 
PPI users, we found a significantly increased risk of hospitalization for CV events for current (aOR 
1.61; 95%CI 1.55-1.68) and recent users (aOR 1.15; 95%CI 1.06-1.26) compared to past users, 
regardless of the type of PPI. Results were consistent in stratified analyses, by type of outcome 
(cardiovascular or cerebrovascular events), by antithrombotic use, and by exposure duration. 
 
A major limitation of an observational study is that statistical analyses can only identify associations 
between independent variables and the outcome of interest, and this limit of our findings is shared 
with the other studies mentioned above, since much of the evidence supporting the association 
between PPI exposure and increased cardiovascular risk stems from pharmacoepidemiological 
studies (28-30). Causal conclusions from observational studies typically require to support 
plausibility through biologic evidence and to exclude confounding. 
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Several possible biologic mechanisms to explain the association have been proposed in literature. 
The most credited hypothesis derived from the observation that an impairment of NOS (Nitric Oxide 
Synthase) pathway resulting in a promotion of ischemic conditions (16, 31, 32). In fact, all PPI class 
members can directly inhibit dimethylarginine dimethylaminohydrolase (DDAH) (31) activity. The 
consequence is an elevation of asymmetric dimethylarginine (ADMA), a circulating inhibitor of NOS, 
justifying the increase in cardiovascular risk, since accumulating evidence from epidemiological 
studies indicates that humans with impaired NOS activity are at greater risk of CV events (33, 34).  
Of note, the studies investigating the association between PPIs and CV risk have paid particular 
attention to the use of strategies, both in the design and in the analysis, that minimized these biases 
(35), such as the adjustment for cardiovascular therapies, use of the propensity score, the new-users 
design (36), the use of H2 antagonists as negative controls (37). A potential source of confounding 
may be an increased use of acid-suppressing drugs in the period before hospitalization, because 
prodromal symptoms of MI could be misinterpreted as dyspepsia (38). Supporting this hypothesis, 
in a case-crossover study showing that PPI prescription enhanced the risk of MI by 70%, this increase 
was mitigated when the dispensation date was considered instead of the prescription date (39). A 
potential factor that must be considered is the confounding by indication, i.e. the possibility that 
the increase in risk is determined by the pathology treated with PPIs, rather than by the drugs 
themselves (40). Indeed, a population-based study reported a risk for cardiovascular adverse events 
with PPI therapy, but it also revealed a risk of similar magnitude with other drugs without known 
cardiac toxicity (41). To account for confounding by indication, in the current study was applied the 
so‐called “user‐only design” by restricting the target population only to patients who used the drug 
of interest making exposed (current users) and non-exposed (past users) groups comparable for 
baseline outcome risk. Notably, in our study subjects treated with PPIs were included regardless of 
indication. Furthermore, the analysis on the effect of H2 antagonist utilization, used as negative 
control since they are prescribed with the same indications, showed no significant results. The same 
approach was adopted by other observational studies that have not shown an increase in risk as 
well (15, 18, 26, 42). 
Another limitation of our study, inherent to the use of administrative databases as sources of data, 
is the impossibility to account for factors related to the pathophysiological status and lifestyle of the 
patient, with the exception of what can be deduced from the use of prescribed drugs. For example, 
we could not take into account the use of low-dose aspirin (which is associated both with a higher 
CV risk and with a higher risk of upper GI bleeding, and therefore of the use of PPIs). This because 
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low-dose aspirin is available both as a reimbursed drug for cardiovascular prevention (therefore 
traceable in administrative databases) and as OTC formulation with analgesic/anti-inflammatory 
indication, and its low cost makes it a largely practiced option. This prevents us from providing 
reliable prevalence estimates of use of low-dose aspirin and using the data as adjustment variable. 
Similarly, information on the use of NSAIDs and coxibs was collected; these covariates were 
intended to be a proxy of the pathological state of the patient, to be included as adjustment 
variables in the multivariate model. With regard to these variables, the modest risk reduction shown 
in our analysis, although evaluated on a cohort of PPI users and without quantifying the exposure, 
may deserve further study.  
As implemented by applying methods based on the propensity score (18, 42), taking these factors 
into account could help to control for some confounding factors. Nevertheless, it should be 
remembered that PPI users tend to be sicker than PPI nonusers, and it is difficult to adjust these 
baseline differences. For this reason, this cause-and-effect relationship between PPI use and CV 
events still should be tested in further detail by a randomized prospective trial. 
 
In conclusion, consistent with the evidence that PPIs may adversely impact vascular function, in this 
study PPI use was independently associated with an increased risk of first-time cardiovascular event 
in the general population. This association certainly deserves further investigation; however, these 
results, along with the most recent evidence suggesting a less favourable safety profile, highlight 
the urgency of critically reviewing the use of PPIs, at least in those situations where their use is not 
recommended. 
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FIGURES 
 
Figure 1. Association between current use of PPIs (vs past use) and risk of hospitalization for cardiovascular 
or non-haemorrhagic cerebrovascular events by age, gender, or concomitant use of drugs 
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TABLES 
 
Table 1. Characteristics of the case patients and of the corresponding controls included into the study  
 Cases (N=17,832) Controls (N=89,160) p-valuea 
Men, % 11,575 (64.91) 57,875 (64.91) MV 
Age, mean (SD) 58.89 (9.05) 58.89 (9.05) MV 
PPIs, % 
Omeprazole 4098 (22.98) 19108 (21.93) 
<.0001 
Pantoprazole 3173 (17.79) 16330 (18.32) 
Lansoprazole 4088 (22.93) 20492 (22.98) 
Rabeprazole 1829 (10.26) 9203 (10.32) 
Esomeprazole 4615 (25.88) 23932 (26.84) 
Combinationsb 29 (0.16) 95 (0.11) 
Drugs for diabetes, % 2978 (16.70) 8307 (9.32) <.0001 
Drugs for hypertension, % 12505 (70.13) 46516 (52.17) <.0001 
Drugs for hypercholesterolemia, % 5818 (32.63) 19040 (21.35) <.0001 
Charlson score 
0 15431 (86.54) 83126 (93.23) 
<.0001 1 1395 (7.82) 4197 (4.71) 
>=2 1006 (5.64) 1837 (2.06) 
Antithrombotics during follow-up 7696 (43.16) 19513 (21.89) <.0001 
Non-selective NSAIDs, % 11594 (65.02) 57822 (64.85) 0,6620 
Coxibs, % 3914 (21.95) 19304 (21.65) 0,3591 
Corticosteroids, % 4993 (28.00) 23630 (26.50) <.0001 
Recency of PPI use, % 
Current use 4386 (24.60) 12828 (14.39) 
<.0001 Recent use 781 (4.38) 3845 (4.31) 
Past use 12665 (71.02) 72487 (81.30) 
MV: matching variables; NSAIDs: nonsteroidal anti-inflammatory drugs; PPIs: proton pump inhibitors 
a According to chi-square test (PPI class, concomitant users of other drugs) or its version for the trend (categories of the Charlson 
comorbidity index score and of recency)  
b More than one PPI at the index date 
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Table 2. Association between PPI use and risk of hospitalization for cardiovascular or non-haemorrhagic 
cerebrovascular events 
 aORsa 95%CI 
Exposure   
Current vs past 1.61 1.55-1.68 
Recent vs past 1.15 1.06-1.26 
Past use 1 ref 
Starting therapy   
Lansoprazole 1 ref 
Omeprazole 0.98 0.93-1.03 
Pantoprazole 0.97 0.92-1.02 
Rabeprazole 0.98 0.92-1.05 
Esomeprazole 0.98 0.93-1.03 
Combinations 1.18 0.76-1.83 
Use of other drugs (vs No use)   
Drugs for diabetes 1.37 1.31-1.44 
Drugs for hypertension 1.77 1.70-1.84 
Drugs for hypercholesterolemia 1.34 1.29-1.40 
Antithrombotics during follow-up 2.37 2.29-2.46 
Non-selective NSAIDs 0.94 0.91-0.98 
Coxibs 0.94 0.90-0.98 
Corticosteroids 1.03 0.99-1.07 
Charlson comorbidity index   
0 1 ref 
1 1.37 1.28-1.47 
≥2 1.83 1.68-1.99 
a Model adjusted for type of PPI, antidiabetic drug use, antihypertensive drug use, lipid-
lowering drug use, NSAID use (except coxibs), coxib use, corticosteroid use, and Charlson 
comorbidity index. 
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Table 3. Association between PPI use and risk of hospitalization for cardiovascular and non-haemorrhagic 
cerebrovascular events  
 aORsa 95%CI 
Cardiovascular 
events 
Current vs Past 1.71 1.63-1.81 
Recent vs Past 1.13 1.02-1.27 
Cerebrovascular 
events 
Current vs Past 1.43 1.34-1.54 
Recent vs Past 1.16 1.01-1.34 
a Model adjusted for type of PPI, antidiabetic drug use, antihypertensive drug use, lipid-
lowering drug use, NSAID use (except coxibs), coxib use, corticosteroid use, and Charlson 
comorbidity index. 
 
 
 
Table 4. Risk of hospitalization for cardiovascular or non-haemorrhagic cerebrovascular events by recency of 
H2 antagonist use 
  aORsa 95% CI 
Recency of H2 antagonist 
use 
Current vs past 0.89 0.51-1.54 
Recent vs past 1.04 0.39-2.78 
a Model adjusted for type of H2 antagonist, antidiabetic drug use, antihypertensive drug 
use, lipid-lowering drug use, NSAID use (except coxibs), coxib use, corticosteroid use, and 
Charlson comorbidity index. 
 
Supplemental Figure 1. Flow chart of inclusion and exclusion criteria 
 
 
  
Supplemental Table 1. Sensitivity analysis: risk of hospitalization for cardiovascular and for non-haemorrhagic 
cerebrovascular events by different definition of recency of PPI use 
 ORs 95%CI 
Recency (B) 
Current vs past 1.67 1.60-1.75 
Recent vs past 1.23 1.11-1.36 
Recency (C) 
Current vs past 1.71 1.63-1.79 
Recent vs past 1.31 1.231-41 
Recency (B) with other windows of exposure: current <=14 days, recent 15-28 days, past >28 days.  
Recency (C) estimated as time between last prescription and event date and current <=28 days, recent 28-56 days, past >56 days 
 
 
 
